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ABSTRACT
Background: Even though time-to-treatment has been
shown to be a determinant of mortality in primary
angioplasty, the potential benefits from early pharmaco-
logical reperfusion by glycoprotein (Gp) IIb–IIIa inhibitors
are still unclear. The aim of this meta-analysis was to
combine individual data from all randomised trials
conducted on facilitated primary angioplasty by the use of
early Gp IIb–IIIa inhibitors.
Methods and results: The literature was scanned by
formal searches of electronic databases (MEDLINE,
EMBASE) from January 1990 to October 2007. All
randomised trials on facilitation by the early administration
of Gp IIb–IIIa inhibitors in ST-segment elevation myocar-
dial infarction (STEMI) were examined. No language
restrictions were enforced. Individual patient data were
obtained from 11 out of 13 trials, including 1662 patients
(840 patients (50.5%) randomly assigned to early and 822
patients (49.5%) to late Gp IIb–IIIa inhibitor administra-
tion). Preprocedural Thrombolysis in Myocardial Infarction
Study (TIMI) grade 3 flow was more frequent with early
Gp IIb–IIIa inhibitors. Postprocedural TIMI 3 flow and
myocardial blush grade 3 were higher with early Gp IIb–
IIIa inhibitors but did not reach statistical significance
except for abciximab, whereas the rate of complete ST-
segment resolution was significantly higher with early Gp
IIb–IIIa inhibitors. Mortality was not significantly different
between groups, although early abciximab demonstrated
improved survival compared with late administration, even
after adjustment for clinical and angiographic confounding
factors.
Conclusions: This meta-analysis shows that pharmaco-
logical facilitation with the early administration of Gp IIb–
IIIa inhibitors in patients undergoing primary angioplasty
for STEMI is associated with significant benefits in terms
of preprocedural epicardial recanalisation and ST-segment
resolution, which translated into non-significant mortality
benefits except for abciximab.
Several randomised trials
1 have shown that pri-
mary angioplasty is superior to thrombolysis in
terms of survival in the treatment of ST-segment
elevation myocardial infarction (STEMI). The
attempts to extend primary angioplasty to the
vast majority of STEMI patients may, however, be
associated with longer delays to treatment, with a
negative impact on survival.
2–5 Adjunctive abcix-
imab has been shown to reduce mortality in
patients undergoing primary angioplasty.
67 The
early administration of glycoprotein (Gp) IIb–IIIa
inhibitors seems even more attractive for the
potential benefits expected from early recanalisa-
tion, which might overcome any potential delay to
mechanical reperfusion.
89The Early Glycoprotein
IIb–IIIa Inhibitors in Primary Angioplasty (EGYPT)
cooperation aimed at performing a comprehensive
meta-analysis of randomised trials based on indi-
vidual patient data to evaluate the benefits of
pharmacological facilitation with Gp IIb–IIIa inhi-
bitors in patients undergoing primary angioplasty
for STEMI.
METHODS
Eligibility and search strategy
We identified all randomised trials comparing
pharmacological facilitation by the early adminis-
tration of Gp IIb–IIIa inhibitors versus its peripro-
cedural administration in STEMI patients
undergoing primary angioplasty. The literature
was scanned by formal searches of electronic
databases (MEDLINE, EMBASE) from January
1990 to October 2007, the scientific session
abstracts in Circulation, Journal of College of
Cardiology, European Heart Journal and American
Journal of Cardiology from January 1990 to October
2007. The following key words were used: rando-
mised trial, myocardial infarction, reperfusion,
primary angioplasty, facilitated angioplasty, Gp
IIb–IIIa inhibitors, abciximab, eptifibatide, tirofi-
ban. No language restrictions were enforced. All
principal investigators were contacted in order to
provide individual patient data, which were
transferred without patient identifiers (initials
and birthday) to the Eastern Piedmont
University, Novara, Italy. The dataset was checked
for completeness and consistency and compared
with the results of any publications. Queries were
resolved by direct correspondence with the study
investigator responsible. Data were managed
according to the intention-to-treat principle.
Angiograms and ECG were not analysed by a
central core laboratory, but data were provided by
each principal investigator. Analysis of angiograms
was based on standard definitions.
10–12 In particular,
distal embolisation was defined as an abrupt ‘‘cut-
off’’ in the main vessel or one of the coronary
branches of the infarct-related artery, distal to the
angioplasty site.
12 Even though ST-segment analysis
was performed according to the pre-specified criteria
of each trial, data were provided according to
uniform thresholds (,30% no resolution; 30%–70%
partial resolution; .70% complete resolution).
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Angiographic endpoints were preprocedural and postprocedural
Thrombolysis in Myocardial Infarction Study (TIMI) grade 3
flow distal embolisation. Myocardial perfusion was evaluated
by myocardial blush grade (MBG) 3 and post-procedural
electrocardiograms were evaluated for complete (.70%) ST-
segment resolution. Infarct size was estimated by using peak
creatine kinase levels. The primary clinical endpoint was
mortality. We also analysed the rate of major bleeding
complications (defined as retroperitoneal, intracranial bleeding,
or a drop in haemoglobin .5 g/dl) as the major safety endpoint.
Data analysis
Statistical analysis was performed using the Review Manager
4.27 freeware package and SPSS 15.0 statistical package. The
pooled odds ratio (OR) for categorical variables was calculated
by using the modified Mantel–Haenszel method with ‘‘observed
minus expected’’ values for each trial, whereas a weighted mean
difference was used for continuous variables.
24 We performed
survival analyses with the use of Cox regression analysis
stratified according to trial.
25 Survival was defined as the
interval from randomisation until the event of interest.
Survival curves are presented as non-stratified Kaplan–Meier
across trials. Heterogeneity across trials was assessed by the I
2
statistics. Prespecified subgroup analyses were performed
according to the molecule (abciximab, tirofiban and eptifiba-
tide). Additional subgroup analyses were performed for mortal-
ity according to diabetic status, age (.65 or ,65 years) and
time to treatment (.3o r,3 h), gender and infarct location
(anterior versus non-anterior).
A multivariate adjustment of mortality benefits was finally
performed for major clinical or angiographic characteristics,
such as age, gender, diabetes, hypertension, smoking, previous
revascularisation, previous myocardial infarction (MI), anterior
MI, Killip class at presentation, time to treatment, time from
symptom onset to Gp IIb–IIIa inhibitor administration, dura-
tion of preprocedural drug administration (from Gp IIb–IIIa
inhibitor administration to balloon angioplasty), type of drug,
multivessel disease, coronary stenting and interaction between
molecules and early drug administration, by using a Cox
regression analysis stratified according to trial (all covariates
were entered in block in the model).
26
RESULTS
Eligible studies
Individual patient data were obtained from 11
13–17 19–23 27 out of
14
25 28 29 trials. A total of 1662 patients were included, 840
patients (50.5%) were randomly assigned to early (administra-
tion started in the ambulance, in the community hospital
before/during transportation to percutaneous coronary inter-
vention (PCI) centres, or in the emergency room/intensive care
unit of PCI hospitals) and 822 patients (49.5%) were randomly
assigned to late (periprocedural) Gp IIb–IIIa inhibitor adminis-
tration.
Study characteristics are reported in table 1. Baseline patient
characteristics are reported in table 2. A total of six trials was
conducted on abciximab (n = 612, 36.8%), three trials on
tirofiban (n = 632, 38%) and two trials on eptifibatide
(n = 418, 25.2%). Baseline patient characteristics according to
study drug are reported in table 3.
Angiographic endpoints
Preprocedural TIMI 3 flow
Data were available fot 1634 patients. As shown in fig 1, early
Gp IIb–IIIa inhibitors were associated with a significantly
improved preprocedural TIMI 3 flow (23.0% versus 13.3%, Peto
OR 1.93; 95% CI 1.50 to 2.48; p,0.001, phet=0.25) with similar
benefits across the three molecules.
Table 1 Characteristics of randomised trials comparing early versus late Gp IIb–IIIa inhibitor administration in primary angioplasty
Study Period Study design (no of patients)
Symptom
duration,
hours Stent Primary endpoints
Follow-up
duration
ReoPro-BRIDGING
13 2003–4 Early (n = 28) versus late (n = 27)
abciximab*
,6 Yes Preprocedural TIMI 3 flow, cTFC and MACE 1 year
RELAx-AMI
14 2003–4 Early (n = 105) versus late (n = 105)
abciximab*
,6 Yes Preprocedural TIMI 3 flow, ST resolution,
myocardial salvage
30 days
Rakowski et al
15 2004 Early (n = 25) versus late (n = 30)
abciximab*
,12 Yes Preprocedural TIMI 3 flow, ST resolution, LVF 1 year
ERAMI
16 2001–2 Early (n = 36) versus late (n = 38)
abciximab)*
,12 nr Preprocedural TIMI flow 1 year
Zorman et al
17 1998–2001 Early (n = 56) versus late (n = 56)
abciximab*
,12 Yes Early (60 minutes) ST-segment resolution,
preprocedural 3 TIMI flow
6 months
REOMOBILE
18 2001–2 Early (n = 52) versus late (n = 48)
abciximab*
,6 Yes Preprocedural TIMI flow 1 year
Cutlip et al
19 2001–2 Early (n = 28) versus late or no (n = 30)
tirofiban{
,12 Yes Preprocedural TIMI flow 30 days
On-TIME
20 2001–2 Early (n = 251) versus late (n = 256)
tirofiban{
,6 Yes Preprocedural TIMI flow 1 year
Emre et al
21 2002–3 Early (n = 32) versus late (n = 34)
tirofiban{
,6 Yes Myocardial perfusion and functional recovery
at 30 days
30 days
INTAMI
22 2002–4 Early (n = 53) versus late or no (n = 49)
eptifibatide{
,12 Yes Preprocedural TIMI 3 flow 1 year
TITAN-TIMI 34
23 2004–5 Early (n = 180) versus late or no
(n = 163) eptifibatide{
,6 Yes Preprocedural TIMI frame count 30 days
*0.25 mg/kg intravenous bolus, followed by 0.125 mg/kg per minute infusion (12 h).
{10 mg/kg intravenous bolus followed by 0.15 mg/kg per minute infusion (24 h).
{180 mg/kg intravenous double bolus followed by 2.0 mg/kg per minute infusion (12–24 h).
cTFC, corrected TIMI frame count; Gp, glycoprotein; LVF, left ventricular function; MACE, major adverse cardiac events; nr, not reported; TIMI 3, Thrombolysis in Myocardial
Infarction Study grade 3 flow.
Acute coronary syndromes
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Data were available for 1551 patients. As shown in fig 2, no
difference was observed in the rate of postprocedural TIMI 3 flow
(90% versus 87.9%, Peto OR 1.24; 95% CI 0.90 to 1.71; p=0.18,
phet=0.57). Early abciximab was, however, associated with a
significant improvement in postprocedural TIMI 3 flow (90.2%
versus 84.1%, Peto OR 1.72; 95% CI 1.07 to 2.77; p=0.03, p
interaction of abciximab versus small molecules 0.057).
Distal embolisation
Data were available for 1181 patients. Early Gp IIb–IIIa
inhibitors were not associated with significant benefits in terms
of distal embolisation (10.1% versus 12.3%, Peto OR 0.84; 95%
CI 0.57 to 1.26; p=0.4, phet=0.32; fig 3), except for abciximab
(12% versus 19%, Peto OR 0.55; 95% CI 0.31 to 0.99; p=0.05, p
interaction of abciximab versus small molecules 0.057).
Myocardial perfusion
Myocardial blush
Data were available for 1324 patients. As shown in fig 4, early
Gp IIb–IIIa inhibitors were associated with slight benefits in
final MBG 3 (49.1% versus 45.8%, Peto OR 1.18; 95% CI 0.95 to
1.47; p=0.14, phet=0.40, number needed to treat 30.3). In an
analysis limited to abciximab trials, the benefits achieved
statistical significance (52.7% versus 41.1%, Peto OR 1.62;
95% CI 1.12 to 2.33; p=0.01; p interaction of abciximab versus
small molecules 0.02).
ST-segment resolution
Data were available for 1371 patients. As shown in fig 5, early
Gp IIb–IIIa inhibitors were associated with significant benefits
in terms of complete ST-segment resolution (60.3% versus
54.1%, Peto OR 1.30; 95% CI 1.04 to 1.62; p=0.02, phet,0.001).
This difference was greater for early versus later abciximab
(52.9% versus 36.1%, Peto OR 1.98; 95% CI 1.43 to 2.75;
p,0.001; p interaction of abciximab versus small molecules
,0.001).
Enzymatic infarct size and abortion of MI
Data on creatine kinase levels were available for 1181 patients.
As shown in fig 6, early Gp IIb–IIIa inhibitors were associated
with a trend in benefits in terms of enzymatic infarct size
(weighted mean difference 2111.5; 95% CI 2229.6 to 76.5;
p=0.25, phet=0.54).
Early Gp IIb–IIIa inhibitors were associated with a non-
significantly higher rate of abortion of MI (9.7% versus 8.1%,
Peto OR 1.04; 95% CI 0.69 to 1.55; p=0.86, phet=0.85; fig 7).
Clinical endpoints
Mortality
Follow-up data were available at 30 days in four trials,
14 19 21 23 at
6 months in one trial
17 and at one year in six trials
13 15 16 18 20 22
(table 1). As shown in fig 8, early Gp IIb–IIIa inhibitors were
associated with non-significantly larger benefits in mortality
(3.7% versus 4.7%; hazard ratio (HR) 0.78; 95% CI 0.49 to 1.26;
Table 2 Patient demographic and clinical characteristics
Variables
Early Gp IIb–IIIa
inhibitors
Late Gp IIb–IIIa
inhibitors
(n = 840) (n = 822)
Age, years
Median 61 61
Range 52–70 52–70
Sex, n (%) 642/840 (76.4%) 641/822 (78.0%)
Hypertension, n (%) 353/838 (42.1%) 347/822 (42.2%)
Diabetes, n (%) 123/840 (14.6%) 135/822 (16.4%)
Previous MI, n (%) 67/838 (8.0%) 80/822 (9.7%)
Previous revascularisation, n (%) 61/792 (7.7%) 59/770 (7.7%)
Smoking, n (%) 440/840 (52.4%) 419/822 (51.0%)
Hypercholesterolemia, n (%) 298/840 (35.5%) 309/820 (37.7%)
Killip class III/IV, n (%) 33/722 (4.6%) 33/705 (4.7%)
Anterior MI, n (%) 361/831 (43.4%) 369/819 (45.1%)
Symptom onset to Gp IIb–IIIa inhibitor time, minutes*
Median 100 197
25–75th percentiles 65–178 144–275
Ischaemia time, minutes
Median 193 203
25–75th percentiles 146–270 150–285
Infarct-related artery
LAD, n (%) 351(41.7%) 361 (43.9%)
CX, n (%) 124 (14.7%) 100 (12.1%)
RCA, n (%) 339 (40.3%) 336 (40.9%)
GRAFT, n (%) 6 (0.7%) 6 (0.7%)
LM, n (%) 4 (0.5%) 5 (0.6%)
Multivessel disease, n (%) 437/757 (57.7%) 433/737 (58.8%)
Follow-up
Median 330 347
25–75th percentiles 30–360 30–360
All p values are not significant except for the time from symptom onset to administration of Gp IIb–IIIa inhibitors* (p,0.001).
CX, circumflex artery; Gp, glycoprotein; LAD, left descending coronary artery; LM, left main artery; MI, myocardial infarction; RCA,
right coronary artery.
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abciximab (2.6% versus 6.5%; HR 0.39; 95% CI 0.17 to 0.9;
p=0.026, phet=0.76; p interaction of abciximab versus small
molecules 0.034; fig 9). The results did not change for either
overall or abciximab after multivariate adjustment (adjusted HR
0.32; 95% CI 0.24 to 4.13; p=0.38; adjusted HR 0,38; 95% CI
0.15 to 1.00; p=0.05, respectively). Additional subgroup
analyses did not show any difference in treatment response
according to the high-risk subsets of patients.
Safety endpoint
No difference was observed in terms of major bleeding
complications (3.2% versus 2.9%, Peto OR 1.13; 95% CI 0.62
to 2.06; p=0.68, phet=0.51).
DISCUSSION
The EGYPT cooperation aimed at performing a meta-analysis to
evaluate the benefits from the early administration of Gp IIb–
IIIa inhibitors in patients undergoing primary angioplasty,
based on individual data of 1662 patients enrolled in 11
randomised trials.
13–23 The main finding of this meta-analysis
is that facilitation with Gp IIb–IIIa inhibitors improved
preprocedural recanalisation. In the analysis limited to the
abciximab trials, there was a significant mortality reduction
with early versus late abciximab administration. It is of note
that other subanalyses also demonstrated improvement in
postprocedural TIMI 3 flow, MBG, distal embolisation and
ST-segment resolution achieved with early abciximab, although
the interaction was statistically significant only for MBG and
improved ST-segment resolution. Comparisons between agents
must be made with extreme caution given the uncontrolled
features of the trials, the possible subtherapeutic dosages
utilised in some of the studies and the differences in timing of
early administration. Also, it must be noted that none of the
studies compared agents, so inferences are based on differences
between early versus late administration for each agent.
Nevertheless, this is the first demonstration of mortality
benefits from pharmacological facilitation in STEMI patients
undergoing primary angioplasty and indicates a need for further
studies to identify the best strategy.
Recent investigations have demonstrated that time to
treatment is a relevant issue in primary angioplasty, with a
significant impact on mortality.
3–5 It has been hypothesised that
the early administration of pharmacological therapy may induce
earlier reperfusion, resulting in reduced infarct size and
improved survival, particularly when long-distance transporta-
tion is required.
89
The ASSENT-4 trial
30 showed harmful effects from facilita-
tion with full-dose tenecteplase in patients undergoing primary
angioplasty, despite improved preprocedural recanalisation.
These data have been explained by a potential intracoronary
prothrombotic rebound at the time of angioplasty induced by
lysis,
31 which could be limited by the administration of Gp IIb–
IIIa inhibitors. These benefits may, however, be counter-
balanced by a larger incidence of bleeding complications,
particularly in elderly patients.
32 Several randomised trials have
been conducted to investigate the benefits from the early
administration of Gp IIb–IIIa inhibitors in patients undergoing
Table 3 Patient demographic and clinical characteristics according to study drug
Variables
Early abciximab Late abciximab Early tirofiban Late tirofiban Early eptifibatide Late eptifibatide
(n = 302) (n = 310) (n = 311) (n = 321) (n = 227) (n = 191)
Age, years
Median 61 62 62 62 58 59
25–75th percentiles 52–69 52–72 54–70 52–70 50–70 51–68
Sex, n (%) 228/302 (75.5%) 239/310 (77.1%) 249/311 (80.1%) 259/321 (80.7%) 165/227 (72.7%) 143/191 (74.9%)
Hypertension, n (%) 143/301 (47.5%) 143/310 (46.1%) 97/311 (31.2%) 110/321 (34.3%) 113/226 (50.0%) 94/191 (49.2%)
Diabetes, n (%) 61/302 (20.2%) 69/310 (22.3%) 37/311 (11.9%) 42/321 (13.1%) 35/227 (15.4%) 37/191 (19.4%)
Previous MI, n (%) 14/301 (4.7%) 26/310 (8.4%) 21/310 (6.8%) 31/321 (9.7%) 32/227 (14.1%) 23/191 (12.0%)
Previous revascularisation, n (%) 9/254 (3.5%) 13/258 (5.0%) 22/311 (7.1%) 22/321 (6.9%) 30/227 (13.2%) 24/191 (12.6%)
Smoking, n (%) 151/302 (50.0%) 146/310 (47.1%) 176/311 (56.6%) 196/321 (61.1%) 113/227 (49.8%) 77/191 (40.3%)
Hypercholesterolemia, n (%) 135/302 (44.7%) 142/309 (46.0%) 78/311 (25.1%) 90/321 (28.0%) 85/227 (37.4%) 77/190 (40.5%)
Killip class III/IV, n (%) 15/302 (4.9%) 14/310 (4.4%) 3/251 (1.2%) 4/256 (1.6%) 15/169 (9.2%) 15/139 (10.8%)
Anterior MI, n (%) 153/302 (50.7%) 157/310 (50.6%) 127/311 (40.8%) 138/321 (43.0%) 81/218 (37.2%) 74/188 (39.4%)
Symptom onset to Gp IIb–IIIa
inhibitor time, minutes*
Median 130 203 64 191 150 199
25–75th percentiles 800–203 145–300 50–85 145–264 95–257 138–267
Ischaemia time, minutes
Median 194 208 193 198 191 210
25–75th percentiles 145–271 150–300 150–249 150–270 138–295 147–303
Infarct-related artery
LAD, n (%) 151 (50%) 153 (49.4%) 123 (39.5%) 134 (41.7%) 77 (33.9%) 74 (38.7%)
CX, n (%) 34 (11.3%) 30(9.7%) 51 (16.4%) 41 (12.8%) 39 (17.2%) 29 (15.2%)
RCA, n (%) 113 (37.4%) 122 (39.4%) 123 (39.5%) 131 (40.8%) 103 (45.3%) 83 (43.5%)
GRAFT, n (%) 0 6 (0.7%) 2 (0.6%) 4 (1.2%) 4 (1.8%) 2 (1.0%)
LM, n (%) 0 3 (1.0%) 4 (1.3%) 1 (0.3%) 0 1 (0.5%)
Multivessel disease, n (%) 120/254 (47.2%) 142/258 (55.0%) 150/282 (53.2%) 147/289 (50.9%) 167/221 (75.6%) 144/190 (75.8%)
Follow-up
Median 180 180 357 356 30 30
25–75th percentiles 30–360 30–360 346–360 342–360 30–30 30–30
All p values are not significant except for the time from symptom onset to administration of Gp IIb–IIIa inhibitors* (p,0.001).
CX, circumflex artery; Gp, glycoprotein; LAD, left descending coronary artery; LM, left main artery; MI, myocardial infarction; RCA, right coronary artery.
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13–23 27–29 As the adjunctive use of Gp IIb–IIIa
inhibitors, mostly abciximab, has been shown to reduce
mortality among patients undergoing primary angioplasty,
67
further benefits would be expected by an early reperfusion
achieved by early drug administration.
A subanalysis of the Abciximab before Direct Angioplasty and
Stenting in Myocardial Infarction Regarding Acute and Long-
Term Follow-up (ADMIRAL) trial showed that early abciximab
administration (in the emergency department or in the
ambulance) did improve clinical outcome compared with late
administration.
33
In a recent meta-analysis performed on pharmacological
facilitation in primary angioplasty, no overall benefits in short-
term (30 days) mortality were observed with inhibitors of Gp
IIb–IIIa inhibitors,
34 and their use was discouraged by the
authors in daily clinical practice, unless in randomised trials.
That meta-analysis did not include all currently available
trials, however, and analysed only a restricted number of
endpoints with a limited duration of follow-up. Furthermore,
no prespecified subanalysis was performed according to the type
of molecule. In a recent smaller meta-analysis, restricted to
abciximab and including randomised trials and non-randomised
subgroup analyses, early abciximab did result in significant
benefits in terms of myocardial perfusion and an increased
number of aborted infarctions but without significant impact
on mortality compared with late administration.
35
Although significantly improved preprocedural recanalisation
was the major benefit of early Gp IIb–IIIa inhibitors, there were
also suggestions of improved myocardial reperfusion. Most
notably, complete ST-segment resolution was significantly
better overall. Several studies have reported an association
between this marker and mortality. Early abciximab, but not
the small molecules, was also associated with increased MBG 3
compared with late use. The underlying mechanisms for these
beneficial effects may be the diminished distal embolisation of
platelet aggregates (as observed in the current meta-analysis) or
inhibition of the direct interaction of platelets with the
reperfused endothelium by abciximab.
36 37
The survival benefits of early Gp IIb–IIIa inhibitors did not
significantly change across most of the subgroups analysed.
Disappointing results have been observed in the Facilitated
Intervention with Enhanced Reperfusion Speed to Stop Events
(FINESSE) trial, recently presented at the 2007 annual meeting
of the European Society of Cardiology.
29 The trial was
prematurely stopped due to slow recruitment, with the
inclusion of up to 2500 STEMI patients. No advantages in
terms of clinical outcome were observed at 3-month follow-up
with facilitation by either combotherapy (abciximab and half-
dose reteplase) or abciximab, compared with late periprocedural
abciximab administration, despite higher patency rates, mainly
with combotherapy. It must be remarked that the FINESSE trial
did include several centres with large variability in experience
and skills, whereas our meta-analysis included trials mainly
conducted at high-volume and highly experienced primary PCI
centres. In addition, the slow recruitment rate observed in the
FINESSE trial (approximately a mean of 10 patients a year
enrolled per centre over 4 years) may have led to a selection
bias. Finally, even though the aim of the trial was to investigate
facilitation, more than 50% of patients were enrolled and
randomly assigned in primary PCI centres. Longer follow-up
Figure 1 Facilitation with early glycoprotein IIb–IIIa inhibitors and preprocedural TIMI flow with Peto odds ratios and 95% CI. The size of the data
markers (squares) is approximately proportional to the statistical weight of each trial. Gp, glycoprotein; IPD, individual patient data; OR, odds ratio;
TIMI, Thrombolysis in Myocardial Infarction Study.
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1552 Heart 2008;94:1548–1558. doi:10.1136/hrt.2008.141648Figure 2 Facilitation with early Gp IIb–IIIa inhibitors and postprocedural TIMI 3 flow with Peto odds ratios and 95% CI. The size of the data markers
(squares) is approximately proportional to the statistical weight of each trial. Gp, glycoprotein; IPD, individual patient data; OR, odds ratio; TIMI,
Thrombolysis in Myocardial Infarction Study.
Figure 3 Facilitation with early Gp IIb–IIIa inhibitors and distal embolisation with Peto odds ratios and 95% CI. The size of the data markers (squares)
is approximately proportional to the statistical weight of each trial. Gp, glycoprotein; IPD, individual patient data; OR, odds ratio.
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Heart 2008;94:1548–1558. doi:10.1136/hrt.2008.141648 1553Figure 4 Facilitation with early Gp IIb–IIIa inhibitors and myocardial blush grade 3 with Peto odds ratios and 95% CI. The size of the data markers
(squares) is approximately proportional to the statistical weight of each trial. *Myocardial perfusion evaluated by myocardial perfusion grade. Gp,
glycoprotein; IPD, individual patient data; OR, odds ratio.
Figure 5 Facilitation with early Gp IIb–IIIa inhibitors and complete ST-segment resolution with Peto odds ratios and 95% CI. The size of the data
markers (squares) is approximately proportional to the statistical weight of each trial. Gp, glycoprotein; IPD, individual patient data; OR, odds ratio.
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1554 Heart 2008;94:1548–1558. doi:10.1136/hrt.2008.141648Figure 6 Facilitation with early Gp IIb–IIIa inhibitors and enzymatic infarct size (peak creatine kinase) with weighted mean difference and 95% CI. The
size of the data markers (squares) is approximately proportional to the statistical weight of each trial. Gp, glycoprotein; OR, odds ratio; WMD, weighted
mean difference.
Figure 7 Facilitation with early Gp IIb–IIIa inhibitors and myocardial abortion with Peto odds ratios and 95% CI. The size of the data markers (squares)
is approximately proportional to the statistical weight of each trial. Gp, glycoprotein; IPD, individual patient data; OR, odds ratio.
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Heart 2008;94:1548–1558. doi:10.1136/hrt.2008.141648 1555data and a more extensive analysis will certainly provide
important additional information before final conclusions can
be drawn from that trial.
The Ongoing Tirofiban in Myocardial Infarction Evaluation 2
(On-TIME-2) trial,
38 investigating the early administration of
high-dose tirofiban, will certainly provide additional important
data on this relevant issue.
Limitations
We were unable to obtain individual patient data from three
randomised trials,
27–29 whereas the ADMIRAL trial was not
included, because it did not compare early versus late admin-
istration of Gp IIb–IIIa inhibitors.
Even though the meta-analysis was based on individual
patient data, this can not overcome the potential heterogeneity
among trials caused by different inclusion and exclusion criteria
and the fact that angiographic and ECG data were not analysed
by a central core laboratory.
Enzymatic infarct size was estimated by peak creatine kinase
levels, whereas the use of scintigraphic techniques would have
potentially improved the results of the meta-analysis. The
beneficial effects observed in terms of preprocedural recanalisa-
tion might have translated into benefits in terms of left
ventricular remodelling and larger survival benefits at long-
term follow-up, such as up to 3–5 years, which unfortunately
were unavailable from current randomised trials.
On the basis of their prognostic implications and availability,
we analysed major but not minor bleeding complications.
High-dose tirofiban has been demonstrated to provide higher
inhibition of platelet aggregation, compared with a standard
bolus dose, as used in trials included in the current meta-
analysis and abciximab.
39 40 Whether the early administration of
Figure 8 (A) Facilitation with early Gp
IIb–IIIa inhibitors and mortality with
pooled hazard ratios and 95% CI. The size
of the data markers (squares) is
approximately proportional to the
statistical weight of each trial. (B)
Kaplan–Meier survival curves according
to early versus late Gp IIb–IIIa inhibitors.
(C) Kaplan–Meier survival curves
according to early versus late Gp IIb–IIIa
inhibitors in trials with abciximab. Gp,
glycoprotein.
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ongoing On-TIME 2 trial.
38
Several factors may have hampered the potential benefits of
early eptifibatide administration, such as the restricted number
of patients and trials included in the current meta-analysis, the
relatively short-term follow-up (available in the vast majority of
patients only at 30 days) and the shorter duration of drug
administration before angioplasty, compared with other Gp IIb–
IIIa inhibitors.
Moreover, it has to be pointed out that this meta-analysis
was primarily performed to evaluate early versus late use of Gp
IIb–IIIa inhibitors with respect to surrogate markers and clinical
endpoints. Given the nature of the randomised studies included
in this meta analysis, head-to-head comparisons suggesting
significant benefit for early abciximab may reflect larger
differences between early versus late abciximab and cannot be
interpreted as reflecting the superiority of abciximab over other
agents.
Finally, as the patients enrolled in the current randomised
trials have for the most part been highly selected, caution
should be exercised in extending the conclusion of this meta-
analysis to the vast majority of STEMI patients undergoing
primary angioplasty. As a result of the higher risk profile,
however, at least similar benefits might potentially be expected
in trial-ineligible compared with trial-eligible patients.
41
CONCLUSIONS
This meta-analysis shows that pharmacological facilitation
with Gp IIb–IIIa inhibitors is associated with significant
benefits in terms of preprocedural epicardial recanalisation.
Despite these beneficial effects, however, early Gp IIb–IIIa
inhibitors did translate into non-significant benefits in survival,
except for abciximab, explained by the improved myocardial
perfusion and less distal embolisation. Therefore, until the
results of additional large randomised trials with long-term
follow-up data become available, pharmacological facilitation
with Gp IIb–IIIa inhibitor administration, particularly abcix-
imab, may be considered in patients undergoing primary
angioplasty for STEMI.
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